brigatinib - alunbrig - in a nutshell.
Published 1 year ago • 120 plays • Length 0:13Download video MP4
Download video MP3
Similar videos
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
3:44
approval of alunbrig offers another option for alk positive nsclc, but further research is needed
-
4:15
nice approval: brigatinib in alk nsclc
-
1:21
nice approval of brigatinib in alk-positive nsclc
-
1:01:56
dr shohbit baijal “alectinib or brigatinib – that is the question”
-
1:39
dr. leach on brigatinib in alk-positive nsclc
-
4:00
alta-1l: final overall survival results of brigatinib vs crizotinib for alk lung cancer
-
2:50
how do alk-inhibitors work in alk-positive lung cancer?
-
6:17
introduction to alk inhibitors
-
5:07
christie’s story: metastatic lung cancer survivor
-
2:05
alta-1l: brigatinib vs crizotinib in nsclc
-
4:28
brigatinib for nsclc, latest research and overcoming complications
-
5:19
brigatinib at disease progression of alk-rearranged nsclc
-
1:52
dr. drilon on the utility of brigatinib in alk nsclc
-
2:13
alk nsclc: brigatinib indication and alta trial
-
2:18
alta-1l: brigatinib is superior to crizotinib in alk nsclc
-
8:16
alta ii trial of brigatinib in alk-rearranged nsclc
-
0:52
dr. rotow on remaining questions with brigatinib in alk nsclc
-
1:30
dr. campelo on health-related qol data with brigatinib in alk nsclc
-
1:38
dr. drilon on the safety profile of brigatinib in alk nsclc
-
3:29
alunbrig
-
1:21
alta-1l: brigatinib vs crizotinib